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Electrode Position and the Clinical Outcome after Bilateral 
Subthalamic Nucleus Stimulation
We compared the surgical outcome with electrode positions after bilateral subthalamic 
nucleus (STN) stimulation surgery for Parkinson’s disease. Fifty-seven patients treated with 
bilateral STN stimulations were included in this study. Electrode positions were determined 
in the fused images of preoperative MRI and postoperative CT taken at six months after 
surgery. The patients were divided into three groups: group I, both electrodes in the STN; 
group II, only one electrode in the STN; group III, neither electrode in the STN. Unified 
Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr stage, and activities of daily 
living scores significantly improved at 6 and 12 months after STN stimulation in both group 
I and II. The off-time UPDRS III speech subscore significantly improved (1.6 ± 0.7 at 
baseline vs 1.3 ± 0.8 at 6 and 12 months, P < 0.01) with least L-dopa equivalent daily 
dose (LEDD) (844.6 ± 364.1 mg/day at baseline; 279.4 ± 274.6 mg/day at 6 months; and 
276.0 ± 301.6 mg/day at 12 months, P < 0.001) at 6 and 12 months after STN deep brain 
stimulation (DBS) in the group I. Our findings suggest that the better symptom relief 
including speech with a reduced LEDD is expected in the patients whose electrodes are 
accurately positioned in both STN.
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INTRODUCTION
The subthalamic nucleus (STN) stimulation has become the 
preferred treatment for the patients with advanced Parkinson’s 
disease (PD) who have intolerable drug-induced side effects or 
motor complications following the long-term use of dopaminer-
gic drugs (1, 2). The precise positioning of the electrodes into 
the STN is important for the good clinical outcome after surgery 
(2). Many approaches including image fusion of CT-MRI, MRI-
MRI, and MRI-brain atlas as well as intraoperative microelec-
trode recording and stimulation have been practiced for the pre-
cise targeting of electrodes (3-7). 
  However, not all the patients have their electrodes positioned 
exactly in the STN after surgery. Therefore clinical outcome may 
differ according to the electrode positions. Possible brain shift 
due to cerebrospinal fluid (CSF) leakage (8-10), electrode arti-
facts in the MRI (11), and possible electrode bending during the 
surgery may make it difficult to precisely localize the center of 
the electrodes at a short-term period after surgery (8-11). Thus 
it is reasonable to estimate the electrode positions at a stable 
period after surgery. However, little has been written in the lit-
erature on the clinical outcome and the electrode position esti-
mated at a stable period after surgery.
  Previously we compared the clinical outcomes at 3 and 6 
months after bilateral STN stimulation with the electrode posi-
tions estimated by the fused images of the pre- and post-opera-
tive MRI taken at 6 months by using mutual information tech-
nique (12). During the study period we noted that the center of 
the electrode’s MRI artifact in the postoperative MRI was differ-
ent from the center of electrode estimated by the postoperative 
CT. Therefore we compared the outcomes at 6 and 12 months 
after bilateral STN stimulation depending on electrode positions 
identified in the fused images of the preoperative MRI and the 
postoperative CT taken at six months after surgery. Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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MATERIALS AND METHODS
Patients
Fifty-seven patients with advanced PD who had been treated 
with bilateral STN stimulation between March 2005 and Octo-
ber 2006 and followed up more than one-year at the Movement 
Disorder Center of Seoul National University Hospital (SNUH) 
were enrolled in this study. The indications of bilateral STN stim-
ulation were advanced PD with at least two cardinal features of 
parkinsonism, a good response to levodopa, drug-induced side 
effects such as dyskinesia, or motor fluctuation, and the unsat-
isfactory management with medication. Patients with severe 
cognitive impairment, ongoing psychiatric problems, an unsat-
isfactory general condition for surgery, or an inability to comply 
with the study protocol, were excluded. 
Clinical evaluation
The patients were evaluated with the use of the Unified Parkin-
son Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) Stage, 
Schwab and England Activities of Daily Living (SEADL), the 
Short Form-36 Health Survey (SF-36), and neuropsychological 
tests (the detailed items were described elsewhere) (13). Evalu-
ations were performed before surgery, at 6 and 12 months after 
surgery, and then every year. The neurological evaluations were 
performed by two neurologists. Patients were assessed in two 
conditions; off- (12-hr medication off) and on-medication (1 to 
3 hr after usual morning dose) conditions. The daily levodopa 
equivalent dose (LEDD) was computed as described elsewhere 
(12). The clinical information of the 57 patients is summarized 
in Table 1. 
Surgical procedure
In all cases, a stereotactic Leksell
®-G frame (Elekta Instruments 
AB, Stockholm, Sweden) was mounted on the head of a patient 
under local anesthesia. Brain images were acquired on a 1.5-T 
Signa system (General Electric Medical System, Milwaukee, WI, 
USA). The STNs were localized by a combination of direct visu-
alization by MRI, microelectrode recording (MER), and stimu-
lation technique as previously described elsewhere (12). The 
quadripolar chronic electrodes (DBS 3389, Medtronic, Minne-
apolis, MN, USA) were indwelled under the local anesthesia and 
the implantable pulse generators (IPG) were then implanted sub-
cutaneously under the general anesthesia in a single session.
  Electrical stimulation was started one day after surgery. The 
stimulation parameters and medications were progressively ad-
justed using an N’vision
® programmer (Medtronic) (12).
Adjustment after bilateral STN stimulation
An examination of the effectiveness and side effects of the four 
contacts of the electrodes was performed using an N’vision
® pro-
grammer (Medtronic) in all patients to select the best contact of 
the electrodes and electrical settings for chronic stimulation by 
neurologists. After turning on the minimal stimulation starting 
at the lowest level around 1.0 volts, the medication and stimula-
tion parameter were optimized to the demand for the best status 
of motor functions in harmony with the DBS programming. 
Image fusion of preoperative MRI and postoperative CT 
Three-dimensional (3-D) spiral stereotactic CT scans (64-chan-
nel Brilliance CT, Philips, Eindhoven, Netherlands) with a 1 mm 
slice thickness were taken 6 months after bilateral STN stimula-
tion to localize the electrodes by image fusion with preoperative 
MRI by using mutual information techniques (Fig. 1) (12, 14-18). 
With CT-MRI image fusion, the electrodes positions were plotted 
on the human brain atlas of Schaltenbrand and Wahren (19). In 
brief, the lateral distance from the midline and the antero-pos-
terior distance from the mid-commissural line to each electrode 
were measured in the reformatted axial images (Fig. 1A). The 
lateral angles of the electrode trajectory from the midline, and 
the antero-posterior angle of the electrode trajectory from the 
line perpendicular to the anterior (AC) - posterior commissural 
(PC) line and the depth of the electrodes are also measured in 
the reformatted coronal (Fig. 1B) and sagittal images (Fig. 1C), 
respectively. 
  Based on the plotted electrode position on the axial view at 
the level of 3.5 mm below the AC-PC line, we categorized the 
electrode positions into three groups: 1) group I, both electrodes 
in the STN (n = 36); 2) group II, only one electrode in the STN 
(n = 16); 3) group III, neither electrode in the STN (n = 5) (Fig. 2). 
The clinical information of the patients in each group is summa-
rized in Table 1. 
Statistical analysis
The primary outcome measures were the total scores and part 
III scores of the UPDRS; the H&Y stage; the SEADL; the dyskine-
sia subscores on part IV of the UPDRS; the LEDD; the SF-36; and 
neuropsychological tests. The secondary measures were the sub-
scores on the part III of the UPDRS. The data for those variables 
were presented as the mean ± standard deviation. Repeated mea-
sured ANOVAs were performed to observe the within-factor ef-
fect of 3 times measured at the baseline before surgery and 6 and 
12 months after surgery and the between-factor effect of 3 groups 
(group I, II, and III) classified by the electrode positions in STN 
on the averages of clinical outcomes with scores.
  For the baseline characteristics of the 57 patients, one-way 
ANOVA and chi-square or Fisher’s exact test were conducted to 
find the 3-group differences in the distribution of continuous 
variables and in the frequency of discrete variables, such as gen-
der. To adjust for multiple comparisons within each outcome, 
we computed P values on Bonferroni correction of each out-
come. All statistical analyses were used in SAS version 9.1 (SAS 
institute, Cary, NC, USA). Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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Table 1. Baseline characteristics of the 57 patients 
Parameters Total (n = 57) Group I (n = 36) Group II (n = 16) Group III (n = 5)
P value
1
(3-group difference)
Gender (number of patients)
   Male
   Female
 
26
31
 
15
21
 
7
9
 
4
1
 
0.268
 
Age (yr)
   Mean ± S.D.
   Range
 
60.1 ± 8.7
28-72
 
60.5 ± 7.8
41-74
  
  57.4 ± 10.7
28-68 
  
65.2 ± 6.4
57-73 
  
0.197
Body weight (kg)
   Mean ± S.D. 
 
  57.8 ± 10.0
 
  57.6 ± 11.5
 
56.6 ± 8.1
 
61.7 ± 6.3
 
0.627
Symptom duration (yr)
   Mean ± S.D.
   Range
 
12.6 ± 5.1
5-32
 
12.6 ± 4.8
5-27
 
11.4 ± 3.5
5-17
 
16.4 ± 9.3
8-32
 
0.154
Duration of medication (yr)
   Mean ± S.D.
   Range
 
11.0 ± 3.8
4-23
 
11.2 ± 4.3
4-23
 
10.1 ± 2.6
5-14
 
12.0 ± 2.4
9-15
 
0.489
LEDD (mg/day)*
   Mean ± S.D.
  
  890.8 ± 404.5
  
  844.6 ± 364.1
  
1038.0 ± 496.6
  
  752.0 ± 276.6
  
0.207
Total UPDRS score
   On-medication
      Mean ± S.D.
      Range
   Off-medication
      Mean ± S.D.
      Range
  
  
  33.5 ± 19.2
5-91
 
  68.7 ± 19.6
22-117
 
 
  32.1 ± 20.7
10-91
 
  68.9 ± 22.1
33-117
 
 
  35.6 ± 19.4
11-65
 
  67.5 ± 13.3
49-84
 
 
  33.5 ± 19.2
5-91
 
  68.7 ± 19.6
22-117
 
 
0.926
 
0.990
UPDRS part III score
   On-medication
      Mean ± S.D.
      Range
   Off-medication
      Mean ± S.D.
      Range
 
 
  21.1 ± 12.8
2-59
 
  40.1 ± 14.4
9-78
 
 
23.3 ± 15.6
7-59
 
  40.4 ± 18.2
13-78
 
 
  23.5 ± 10.2
11-39
 
39.8 ± 8.4
28-49
 
  
  21.1 ± 12.8
2-59
 
  40.1 ± 14.4
9-78
 
 
0.606
 
 
0.995
Hoehn & Yahr Stage
   On-medication
      Mean ± S.D.
      Range
   Off-medication
      Mean ± S.D.
      Range
 
 
  2.4 ± 0.7
1-4
 
  3.3 ± 0.9
2-5
 
  
  2.3 ± 0.7
1-4
 
  3.2 ± 0.8
2-5
 
 
  2.7 ± 0.8
2-4
 
  3.8 ± 0.4
3-4
  
 
  2.4 ± 0.7
1-4
 
  3.3 ± 0.9
2-5
  
  
0.577
 
 
0.390
 
Schwab& England ADL
   On-medication
      Mean ± S.D.
      Range
   Off-medication
      Mean ± S.D.
      Range
 
 
  79.7 ± 15.2
30-100
 
  50.4 ± 20.8
10-90
 
 
  83.4 ± 16.4
40-100
 
  48.4 ± 23.1
10-80
 
 
  81.0 ± 11.4
70-100
 
  44.0 ± 15.2
20-60
 
 
   79.7 ± 15.2
30-100
 
  50.4 ± 20.8
10-90
  
 
0.483
 
 
0.659
Good awake time (%) 
   Mean ± S.D.
   Range
Dyskinesia disability
   Mean ± S.D.
   Range
 
  57.1 ± 20.1
16.7-100
 
  2.2 ± 1.4
0-4
 
  58.7 ± 20.1
25-100
 
  2.1 ± 1.4
0-4
 
  58.1 ± 19.8
20.8-83.3
 
  2.3 ± 1.5
0-4
 
  42.5 ± 19.2
16.7-66.7
 
  3.2 ± 0.8
2-4
  
0.236
 
 
0.253
1For gender (discrete scale), the P value was estimated by chi-square test; For other variables (continuous scale), the P value was estimated by ANOVA (Analysis of Variances). 
*Daily levodopa equivalent dose (LEDD) was calculated for each antiparkinsonian medication by multiplying the total daily dosage of each drug by its potency relative to a stan-
dard levodopa preparation assigned at the value of 1. The following conversion factors were used: levodopa controlled release = 0.77, bromocriptine = 10, ropinirole = 20, 
pramipexole = 100, and pergolide = 100. One patient had a cardiac pacemaker for the sick sinus syndrome prior to STN DBS. Two patients had previous thalamotomy. ADL, 
Activities of Daily Life; LEDD, Daily levodopa equivalent dose; UPDRS, Unified Parkinson’s Disease Rating Scale.
Ethical statement
The institutional review board of SNUH approved this study (IRB 
number:H-0711-023-225). This study is exempted from receiv-
ing patient consents due to retrospective review of medical re-
cords.
RESULTS
Primary outcome after bilateral STN stimulation 
The outcomes were compared between preoperative and post-
operative status at 6 and 12 months after bilateral STN stimula-Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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tion (Table 2). Significant improvement in off-time scores of to-
tal UPDRS, UPDRS III, H&Y scores, SEADL, and dyskinesia dis-
ability with decreased LEDD was observed at 6 and 12 months 
after surgery in the group I and II or as a whole group. The LEDD 
tended to be low in the patients of group I at 6 and 12 months 
after surgery (844.6 ± 364.1 at baseline; 279.4 ± 274.6 at 6 months; 
and 276.0 ± 301.6 at 12 months; P-interaction = 0.023). 
  Regarding the eight sub-scales of the SF-36, the scores of bodi-
ly pain and summary scores of physical health improved at 6 
and 12 months after surgery in the patients as a whole group. 
From the neuropsychological evaluation, the verbal memory 
test using Rey-Kim memory battery showed the decline in rec-
ognition at 6-month follow up in the patients as a whole group 
(P = 0.002), whereas nonverbal memory showed no meaning-
ful change. In frontal lobe function tests, the Stroop test (Stroop-
a, P = 0.006; Stroop-b, P = 0.004; Stroop-c, P = 0.034) and the 
fluency test (P = 0.013) tended to aggravate at 6 and 12 months 
after the surgery, especially in the group III (P = 0.046 for Stroop-
a; P = 0.053 for fluency), but lacked statistical significance after 
a Bonferroni correction. Other tests including Boston Naming 
test, Grooved Pegboard test, Mini-Mental state examination, 
Trail-Making test, Beck Depression Inventory, and Wisconsin 
Card Sorting test, did not show significant changes.
  The average stimulation parameters of the patients as a whole 
A C B
Fig. 1. Fused images of the preoperative MRI and postoperative CT. The T2-weighted axial images of brain MRI taken before surgery are fused with 3-D spiral CT scan images 
at the data set of 1-mm thickness reformatted images, aligned to anterior commissure - posterior commissure (AC-PC) line. The midline of reformatted coronal images also in-
tersect the midsagittal plane for the correction of head-rotation error. The length of AC-PC line and width of the third ventricle are taken into consideration for the proportional 
localization of the electrodes position in the human brain atlas of Schaltenbrad and Wahren. In the reformatted axial images the lateral distance from the midline and the antero-
posterior distance from the mid-commissural line to each electrode are measured (A). In the reformatted coronal images in which the electrode trajectory is best visualized, the 
lateral angles of the electrode trajectory from the midline are measured for each electrode in every patient (B). In the reformatted sagittal images in which the electrode trajec-
tory is best shown, the antero-posterior angle of the electrode trajectory from the line perpendicular to the AC-PC line and the depth of the electrodes are also measured for 
each electrode in every patient (C). 
A C B
Fig. 2. Plotting of electrode positions in the human brain atlas. With the information from the fused images of preoperative MRI and postoperative CT taken at 6 months after 
surgery as shown in Fig. 1, the electrode positions are plotted on the human brain atlas of Schaltenbrand and Wahren in each patient. Representative illustration of the elec-
trode positions (A-C) are plotted in the axial, sagittal, and coronal planes. Based on the axial view at the level of 3.5 mm below the AC-PC line in the atlas, electrode positions (in 
blue and red colors) are categorized into three groups: 1) group I, both electrodes in the STN (n = 36) (A); 2) group II, only one electrode in the STN (n  = 16) (B); 3) group III, 
neither electrode in the STN (n = 5) (C). Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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group are 2.6 V (± 0.6 V) in amplitude, 60.6 µsec (± 4.4 µsec) in 
pulse width, and 139.1 Hz (± 15.7 Hz) in frequency. The average 
stimulation parameters of the patients in group I are 2.6 V (± 0.6 
V) in amplitude, 60.5 µsec (± 3.8 µsec) in pulse width, and 137.6 
Hz (± 15.2 Hz) in frequency. The average stimulation parame-
ters of the patients in group II are 2.6 V (± 0.6 V) in amplitude, 
61.3 µsec (± 6.1 µsec) in pulse width, and 142.0 Hz (± 17.0 Hz) 
in frequency. The average stimulation parameters of the patients 
in group III are 2.2 V (± 0.9 V) in amplitude, 60.0 µsec (± 6.0 µsec) 
in pulse width, and 140.5 Hz (± 16.2 Hz) in frequency.
UPDRS part III subscores after bilateral STN stimulation 
The subscores of UPDRS III were compared between preopera-
tive and postoperative status at 6 and 12 months after bilateral 
STN stimulation (Table 3). The off- and on-time tremor and ri-
gidity, the off-time bradykinesia, the off-time gait and postural 
stability subscores significantly improved at 6 months and 12 
months after surgery in the group I and II or as a whole group. 
  The off-time UPDRS III spe ech subscore significantly im-
proved at 6 and 12 months after STN DBS in the group I (1.6 ±  
0.7 at baseline vs 1.3 ± 0.8 at 6 and 12 months; P < 0.01 by paired 
t-tests) (P-interaction = 0.008). But no significant improvement 
was observed in other groups. We further confirmed the speech 
improvement by comparing the sum of the speech subscores of 
UPDRS-II and UPDRS-III between preoperative and postoper-
ative status at 12 month after STN DBS in three groups (P for 
trend = 0.003) (Table 4). 
Outcomes of 13 patients with nil LEDD after bilateral STN 
stimulation
Among 57 patients, the LEDD of 13 patients was zero at their last 
follow up. Their preoperative characteristics were not different 
from the other patients. Their total UPDRS scores, H&Y Stage, 
SEADL, and dyskinesia disability scores dramatically improved 
at 12 months after STN DBS (Table 5). Their off-time UPDRS part 
III subscores including speech were significantly improved at 
Table 2. The clinical outcomes of 57 patients after bilateral subthalamic nucleus stimulation
Medi-
cation
Total subjects Subjects according to each group
Baseline 6 months
1 12 months
1 P value
2  Group Baseline 6 months
1 12 months
1
P value
2 
for 
within- 
factor
P value
3 
for 
group-
factor
P value
4 
for 
interac-
tion
Total UPDRS On
 
 
Off
 
 
33.5 ± 19.2 
 
 
68.7 ± 19.6
†
 
 
29.3 ± 13.7
 
 
46.7 ± 18.3
 
 
29.4 ± 14.0
 
 
42.6 ± 17.0
 
 
0.079
 
 
< 0.001*
 
 
I
II
III
I
II
III
33.9 ± 19.1
32.1 ± 20.7
35.6 ± 19.4
68.8 ± 19.7
†
68.9 ± 22.1
†
67.5 ± 13.3
28.3 ± 14.8
30.4 ± 10.9
32.9 ± 15.0
44.4 ± 18.7
50.5 ± 18.0
51.2 ± 17.4
28.1 ± 14.6
29.8 ± 11.9
37.0 ± 15.6
39.5 ± 17.9
43.4 ± 12.0
62.5 ± 11.2
†
0.717
 
 
< 0.001*
 
 
0.421
 
 
0.368
 
 
0.840
 
 
0.063
 
 
UPDRS III On
 
 
Off
 
 
21.1 ± 12.8
†
 
 
40.1 ± 14.4
†
 
 
16.0 ± 9.2
 
 
23.7 ± 12.4
 
 
16.1 ± 8.2
 
 
21.3 ± 9.3
 
 
0.003*
 
 
< 0.001*
 
 
I
II
III
I
II
III
19.8 ± 11.9
23.3 ± 15.6
23.5 ± 10.2
40.0 ± 13.6
† 
40.4 ± 18.2
†
39.8 ± 8.4
16.2 ± 9.9
15.4 ± 7.9
16.9 ± 8.3
†
23.1 ± 12.9
24.1 ± 11.7
26.4 ± 13.3
15.3 ± 9.2
16.4 ± 5.4
20.6 ± 7.2
20.1 ± 10.0
21.6 ± 7.2
28.5 ± 8.1
0.016*
 
 
< 0.001*
 
 
0.578
 
 
0.703
 
 
0.601
 
 
0.746
 
 
Hoehn & 
   Yahr Stage
On
 
 
Off
 
 
2.4 ± 0.7
 
 
3.3 ± 0.9
†
 
 
2.3 ± 0.7
 
 
2.6 ± 0.7
 
 
2.4 ± 0.7
 
 
2.6 ± 0.6
 
 
0.815
 
 
< 0.001*
 
 
I
II
III
I
II
III
2.4 ± 0.7
2.4 ± 0.7
2.7 ± 0.8
3.3 ± 0.9
†
3.3 ± 0.9
†
3.8 ± 0.4
2.3 ± 0.6
2.2 ± 0.7
2.6 ± 1.1
2.6 ± 0.7
2.5 ± 0.7
3.1 ± 1.1
2.3 ± 0.7
2.3 ± 0.4
3.1 ± 0.5
†
2.5 ± 0.5
2.5 ± 0.5
3.3 ± 1.0
†
0.431
 
 
< 0.001*
 
 
0.146
 
 
0.088
 
 
0.522
 
 
0.792
 
 
Schwab & 
   England ADL
On
 
 
Off
 
 
79.7 ± 15.2
 
 
50.4 ± 20.8
†
 
 
82.0 ± 15.3
 
 
66.4 ± 18.6
 
 
83.0 ± 13.5
 
 
71.2 ± 18.7
 
 
0.325
 
 
< 0.001*
 
 
I
II
III
I
II
III
77.9 ± 15.2
†
83.8 ± 16.0
81.0 ± 11.4
52.1 ± 20.7
†
45.6 ± 25.2
†
40.0 ± 15.2
84.4 ± 11.3
78.7 ± 16.4
74.0 ± 31.3
68.3 ± 16.6
64.7 ± 21.3
58.0 ± 24.9
84.4 ± 11.1
84.4 ± 8.9
68.0 ± 29.5
†
73.9 ± 18.9
72.5 ± 12.4
48.0 ± 21.9
†
0.769
 
  
0.003*
 
 
0.320
 
 
0.061
 
 
0.036*
 
 
0.493
 
 
Dyskinesia 
   disability
2.2 ± 1.4
†
 
 
0.8 ± 1.2
 
 
1.0 ± 1.4
 
 
< 0.001*
 
 
I
II
III
2.1 ± 1.4
†
2.3 ± 1.5
†
3.2 ± 0.8
0.8 ± 1.2
0.5  ± 1.2
1.2 ± 1.8
0.9 ± 1.3
1.1 ± 1.5
1.4 ± 1.9
< 0.001*
 
 
0.306
 
 
0.718
 
 
LEDD (mg/day) 890.8 ± 404.5
†
 
 
344.3 ± 317.8
 
 
340.0 ± 322.6
 
 
< 0.001*
 
 
I
II
III
844.6 ±364.1
†
1038.0±496.6
†
750.0 ± 276.6
279.4 ± 274.6
373.5 ± 269.8
724.0 ±502.9
†
276.0 ± 301.6
396.1 ± 241.1
691.3 ±574.0
†
< 0.001*
 
 
0.149
 
 
0.023*
 
 
All data was expressed as a mean ± standard deviation. *P < 0.05. The bold-faced P values were statistically significant (P < 0.005) after Bonferroni multiple comparison cor-
rection of 10 clinical outcomes; 
†significant different group among three groups or three repeated measured outcomes in the repeated measures ANOVA. 
1, with DBS stimula-
tion; 
2, P value for within-factor of three repeated measured outcomes at the baseline and 6 and 12 months after bilateral STN stimulation; 
3, P value for between-group-factor 
of three groups: I (both electrodes in the STN), II (only 1 electrode in the STN) and III (neither electrode in the STN); 
4, P value for interaction between the within-factor and be-
tween-group-factor. Abbreviations as Table 1.Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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Table 3. UPDRS-III subscores of 57 patients after bilateral subthalamic nucleus stimulation
Total subjects Subjects according to each group (group 1, n = 36; group 2, n = 16; group 3, n = 5)  
Medi-
cation
Baseline 6 months
1 12 months
1 P value
2  Group Baseline 6 months
1 12 months
1
P value
2  
for  
group-
factor
P value
3 
for 
group-
factor
P value
4 
for 
group-
factor
Speech On
   
 
Off
 
 
1.2 ± 0.7
 
 
1.5 ± 0.7
 
 
1.2 ± 0.8
 
 
1.4 ± 0.8
 
 
1.3 ± 0.9
 
 
1.4 ± 0.8
 
 
0.772
 
 
0.119
 
 
I
II
III
I
II
III
1.2 ± 0.8
1.3 ± 0.6
1.1 ± 0.9
1.6 ± 0.7
‡
1.5 ± 0.5
1.3 ± 0.9
1.1 ± 0.8
1.4 ± 0.8
1.9 ± 1.1
†
1.3 ± 0.8
‡
1.6 ± 0.6
2.1 ± 0.7
†
1.2 ± 0.9
1.4 ± 0.8
1.9 ± 1.1
1.3 ± 0.8
‡
1.4 ± 0.7
1.9 ± 1.1
0.103
 
 
0.388
 
 
0.171
 
 
0.402
 
 
0.060
 
 
0.008*
  
 
Tremor On
 
 
Off
 
 
2.4 ± 2.9
†
 
 
6.2 ± 5.2
†
 
 
0.5 ± 1.4
 
 
1.6 ± 2.8
 
  
0.3 ± 0.9
 
 
0.7 ± 1.7
 
 
< 0.001*
 
 
< 0.001*
 
 
I
II
III
I
II
III
2.0 ± 3.0
†
2.8 ± 2.8
†
3.0 ± 2.8
†
5.6 ± 5.1
†
7.3 ± 5.6
†
7.2 ± 4.5
†
0.6 ± 1.6
0.3 ± 0.6
0.2 ± 0.4
1.4 ± 2.2
2.5 ± 4.0
0.4 ± 0.9
0.4 ± 1.0
0.3 ± 0.7
0.2 ± 0.5
0.5 ± 1.5
1.3 ± 2.4
0.3 ± 0.7
< 0.001*
 
 
< 0.001*
 
 
0.888
 
 
0.230
 
 
0.385
 
 
0.583
 
 
Rigidity On
 
 
Off
 
 
4.1 ± 3.6
†
 
 
7.9 ± 3.9
†
 
 
2.7 ± 3.4
 
 
4.3 ± 3.9
 
 
2.5 ± 2.7
 
 
3.5 ± 3.3
 
 
0.004*
 
 
< 0.001*
 
 
I
II
III
I
II
III
3.4 ± 3.3
5.2 ± 4.4
5.5 ± 2.5
7.4 ± 3.9
†
9.2 ± 4.3
†
8.2 ± 2.5
2.7 ± 3.6
2.7 ± 2.9
2.6 ± 4.0
4.2 ± 4.0
4.2 ± 3.6
5.0 ± 4.7
2.0 ± 2.6
3.3 ± 2.8
3.2 ± 3.7
3.2 ± 3.4
3.8 ± 3.2
4.8 ± 3.0
0.007*
 
 
< 0.001*
 
 
0.275
 
 
0.526
 
 
0.481
 
 
0.772
 
 
Bradykinesia On
 
 
Off
7.7 ± 5.3
 
 
13.2 ± 6.6
†
 
 
6.6 ± 5.3
 
 
9.0 ± 5.9
 
 
6.7 ± 4.4
 
 
8.9 ± 4.7
 
 
0.222
 
 
< 0.001*
 
  
I
II
III
I
II
III
7.8 ± 5.2
7.9 ± 6.2
6.5 ± 3.4
14.3 ± 6.4
†
11.5 ± 7.3
10.9 ± 4.8
7.8 ± 5.2
5.7 ± 4.7
5.8 ± 3.9
9.3 ± 6.2
8.3 ± 5.8
9.1 ± 5.0
6.7 ± 4.9
6.3 ± 3.6
8.2 ± 3.0
8.8 ± 5.3
8.6 ± 4.0
11.3 ± 2.8
0.394
 
 
0.006*
 
 
0.965
 
 
0.744
 
 
0.606
 
 
0.211
 
 
Gait On
Off
 
 
0.8 ± 0.7
 
 
1.9 ± 0.9
†
 
 
0.9 ± 0.7
 
 
1.3 ± 0.8
 
 
1.0 ± 0.7
 
 
1.3 ± 0.9
 
 
0.104
 
 
< 0.001*
 
 
I
II
III
I
II
III
0.7 ± 0.6
0.9 ± 0.9
0.8 ± 0.8
1.9 ± 1.0
†
1.8 ± 0.8
1.9 ± 0.7
0.8 ± 0.7
1.0 ± 0.8
0.9 ± 0.7
†
1.3 ± 0.8
1.4 ± 0.7
1.4 ± 1.7
0.9 ± 0.7
1.1 ± 0.7
1.5 ± 0.7
†
1.2 ± 0.7
1.4 ± 0.9
2.1 ± 1.2
†
0.053
 
 
0.019*
 
 
0.436
 
 
0.547
 
 
0.556
 
 
0.287
 
 
Postural 
   stability
On
 
 
Off
 
 
1.1 ± 0.8
†
 
 
1.8 ± 0.9
†
 
 
0.7 ± 0.8
 
 
1.2 ± 0.9
 
 
0.8 ± 0.8
 
 
1.1 ± 0.9
 
 
0.007*
 
 
< 0.001*
 
 
I
II
III
I
II
III
1.1 ± 0.8
†
1.1 ± 0.9
1.5 ± 0.7
†
1.8 ± 1.0
†
1.8 ± 0.8
† 
2.0 ± 0.7
0.7 ± 0.8
0.7 ± 0.7
1.2 ± 0.8
1.2 ± 0.9
1.1 ± 0.8
1.6 ± 0.9
0.8 ± 0.8
0.6 ± 0.8
1.6 ± 0.6
†
1.0 ± 0.8
0.9 ± 0.8
2.1 ± 0.5
†
0.116
 
 
0.001*
 
 
0.105
 
 
0.173
 
 
0.648
 
 
0.241
 
 
All data was expressed as a mean ± standard deviation. *P < 0.05. The bold-faced p-values were statistically significant (P < 0.004) after Bonferroni multiple comparison cor-
rection of 12 UPDRS III subscores. 
†significant different group among three groups or three repeated measured outcomes in the repeated measures ANOVA with post-hoc tests. 
‡The speech subscore at 6 months or at 12 months was significantly lower than that at baseline (paired t-test, P < 0.001 for 6 months vs baseline; P < 0.001 for 12 months 
vs baseline). 
1, with DBS stimulation; 
2, P value for within-factor of three repeated measured outcomes at the baseline and 6 months and 12 months after bilateral STN stimula-
tion; 
3, P value for between-group-factor of three groups: I (both electrodes in the STN), II (only 1 electrode in the STN) and III (neither electrode in the STN); 
4, P value for inter-
action between the within-factor and between-group-factor effects.
Table 4. Speech outcomes of 57 patients after bilateral subthalamic nucleus stimulation
Group I Group II Group III Total
Aggravated 13 (36%) 11 (69%) 5 (100%) 28 (49%)
Stationary   5 (14%) 1 (6%) 0   7 (12%)
Improved 18 (50%)   4 (25%) 0 22 (39%)
Total 36 16 5 57
Mantel-Haenszel chi-square test for trend, chi-square value = 8.819 (degree of free-
dom = 1), P value = 0.003. Three groups were classified by the fused images of 
preoperative MRI and postoperative CT scans taken six months after surgery: group I, 
both electrodes in the STN; group II, only 1 electrode in the STN; group III; neither 
electrode in the STN. The assessment of speech improvement was based on the 
summation of the speech subscores of UPDRS part II and part III. All patients were 
evaluated at 12 months after bilateral STN stimulation.
12 months after surgery (Table 6). Looking into their electrode 
position, all patients have both electrodes mostly positioned into 
middle one third of the STN on axial view at the level of 3.5 mm 
below the AC-PC line (Fig. 3A). The x, y, z coordinates of the ac-
tive contacts referenced to the AC-PC midpoint in these patients 
are depicted in Fig. 3B. The mean (SD) x, y, z coordinates of ac-
tive contacts were 12.6 (1.5), -1.2 (1.0), and 3.6 (0.9) on the left 
electrodes and 12.0 (1.8), -0.5 (0.9), and 3.7 (1.1) on the right elec-
trodes.
Complications
Thirteen (22.8%) of 57 patients had complications after surgery. Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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Transient confusion and abulia was the most common (7.0%) 
followed by transient dysarthria (5.3%). Two patients (3.5%) had 
wound infection, one in the scalp and the other in the left sub-
clavicular area which was well controlled with antibiotic thera-
py. Intracerebral hematomas were found in two patients (3.5%) 
on immediate postoperative CT scans, which were asymptom-
atic. Other complications were seizure (1.8%), transient hypo-
phonia (1.8%), transient restless leg syndrome (1.8%) and per-
manent personality change (1.8%).
DISCUSSION
Most studies in the literature correlated the clinical improve-
ment with the localization of the electrodes determined by the 
fused images of preoperative and postoperative brain CT or MRI 
taken at the immediate postoperative period (5, 15, 20-26). But 
the immediate postoperative imaging make it difficult to pre-
cisely localize the center of electrodes in relation to the STN be-
cause of brain shift due to CSF leakage at the immediate post-
operative period or the electrode artifacts caused by the elec-
Table 5. Clinical outcomes of nil-LEDD patients after bilateral subthalamic nucleus stimulation
Medi-
cation
Group
† Baseline
On -DBS stimulation Off -DBS stimulation
Baseline vs On 
-DBS stimulation
Baseline vs Off 
-DBS stimulation 
6 months 12 months 6 months 12 months
P value
1 
for  
within- 
factor
P value
2 
for  
group-
factor
P value
3
for  
interac-
tion
P value
1 
for  
within- 
factor
P value
2 
for  
group-
factor
P value
3
for  
interac-
tion
Total UPDRS
 
On
  
Off
  
nil-LEDD  
Others
nil-LEDD  
Others
42.8 ±
24.5
30.9 ±
16.8
74.3 ±
25.3
†
67.0 ±
17.6
†
29.6 ±
15.4
29.2 ±
13.4
42.7 ±
18.4
47.9 ±
18.3
32.9 ±
13.8
28.3 ±
14.0
39.1 ±
18.6
43.6 ±
16.6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.016*
   
< 0.001*
  
0.171
  
0.853
 
0.105
  
0.051
 
 
 
 
 
  
  
  
 
  
  
   
 
  
 
  
UPDRS III On
 
Off
 
nil-LEDD  
Others
nil-LEDD  
Others
21.5 ±
17.1
20.9 ±
11.5
†
41.9 ±
18.3
†
39.5 ±
13.2
†
16.8 ±
10.5
15.8 ±
8.9
21.6 ±
12.7
24.3 ±
12.4
16.6 ±
10.9
15.9 ±
7.3
19.2 ±
11.0
21.9 ±
8.7
29.4 ±
12.0
29.6 ±
15.9
35.3 ±
15.5
35.8 ±
15.5
33.8 ±
17.2
27.8 ±
11.3
37.0 ±
17.2
34.1 ±
11.9
0.017*
 
< 0.001*
0.798
 
0.724
0.961
 
0.364
< 0.001*
0.012*
0.553
0.702
0.346
0.679
Hoehn & 
   Yahr Stage
On
Off
nil-LEDD  
Others
nil-LEDD  
Others
2.2 ±
0.8
2.4 ±
0.7
3.1 ±
1.1
3.4 ±
0.8
†
2.3 ±
0.6
2.3 ±
0.7
2.6 ±
0.7
2.6 ±
0.7
2.4 ±
0.6
2.3 ±
0.7
2.4 ±
0.6
2.6 ±
0.6
3.2 ±
1.1
2.8 ±
0.9
3.5 ±
1.2
3.1 ±
1.0
3.1  ±
1.2
2.7 ±
0.7
3.2 ±
1.2
2.9 ±
0.8
0.884
< 0.001*
0.778
0.320
0.354
0.410
< 0.001*
0.177
0.346
0.704
0.062
0.038
Schwab & 
   England ADL
On
 
Off
 
nil-LEDD  
Others
nil-LEDD
Others
70.8 ±
19.8
82.4 ±
12.7
51.7 ±
24.4
†
50.0 ±
20.0
†
80.8 ±
13.2
82.3 ±
16.0
66.5 ±
19.0
66.5 ±
19.0
80.8 ±
11.9
83.6 ±
14.0
77.7 ±
15.4
69.3 ±
19.3
0.072
 
< 0.001*
0.128
0.343
0.122
0.565
Dyskinesia 
   disability
LEDD (mg/
   day)
nil-LEDD
Others
nil-LEDD  
Others
1.9 ±
1.7
†
2.3 ±
1.3
†
860.3 ±
448.4
899.8 ±
395.8
0.5 ±
1.1
0.8 ±
1.3
106.9 ±
174.8
416.1 ±
317.5
0.6 ±
1.3
1.1 ±
1.4
66.9 ±
130.9
422.5 ±
318.3
< 0.001*
< 0.001*
0.172
0.011*
0.903
0.023*
All data was expressed as a mean ± standard deviation. *P < 0.05. The bold-faced P values were statistically significant after Bonferroni multiple comparison correction (P <    
0.005 for comparison between Baseline and On-DBS stimulation for 10 clinical outcomes; P < 0.01 for comparison between Baseline and Off-DBS stimulation for 4 clinical 
outcomes); 
†13 patients are in nil-LEDD and 44 patients are in the other group. 
1, P value for within-factor of three repeated measured outcomes at the baseline and 6 months 
and 12 months after bilateral STN stimulation; 
2, P value for between-group-factor of three groups: I (both electrodes in the STN), II (only 1 electrode in the STN) and III (neither 
electrode in the STN); 
3, P value for interaction between the within-factor and between-group-factor. Abbreviations as Table 1.Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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trode-induced magnetic inhomogeneity (8, 9-11). Miyagi et al. 
confirmed the significant contralateral brain shift in the unilat-
eral procedure and posterior shift in the bilateral procedure by 
comparing the three-dimensional coordinated of the AC and 
PC on MRIs before and after implantation of the electrodes (10). 
Khan et al. (9) reported a shift of deep brain structures up to 4 
mm after the surgery. Halpern et al. (8) reported posterior shift 
of the deep brains structures had impacted the number of mi-
Table 6. UPDRS-III subscores of nil-LEDD patients after bilateral subthalamic nucleus stimulation
Medi-
cation
Group
† Baseline
On -DBS stimulation Off -DBS stimulation
Baseline vs On -DBS 
stimulation
Baseline vs Off -DBS 
stimulation 
6 months 12 months 6 months 12 months
P value
1 
for  
within- 
factor
P value
2 
for 
group-
factor
P value
3 
for  
interac-
tion
P value
1 
for  
within- 
factor
P value
2 
for 
group-
factor
P value
3 
for  
interac-
tion
Speech On
Off
nil-LEDD  
Others
nil-LEDD  
Others
1.3 ±
0.6
1.2 ±
0.8
1.7 ±
0.6
†
1.5 ±
0.7
1.0 ±
0.5
1.3 ±
0.9
1.1 ±
0.5
1.5 ±
0.8
1.0 ±
0.6
1.4 ±
1.0
1.4 ±
0.7
1.4 ±
0.8
1.2 ±
0.4
1.5 ±
0.8
1.3 ±
0.4
1.6 ±
0.8
1.3 ±
0.7
1.3 ±
0.9
1.4 ±
0.7
1.5 ±
0.8
0.460
0.003*
0.326
0.317
0.086
0.007*
0.818
0.313
0.811
0.605
0.310
0.050
Tremor On
Off
nil-LEDD  
Others
nil-LEDD  
Others
2.7 ±
4.1
2.3 ±
2.5
†
5.7 ±
5.1
†
6.4 ±
5.2
†
1.0 ±
2.4
0.3 ±
0.8
1.6 ±
2.9
1.6 ±
2.7
0.4 ±
0.9
0.3 ±
0.9
0.5 ±
1.0
0.7 ±
1.9
1.8 ±
3.7
2.1 ±
3.5
2.9 ±
4.3
3.3 ±
4.0
2.8 ±
4.0
1.9 ±
3.1
3.2 ±
3.9
2.5 ±
3.7
< 0.001*
< 0.001*
0.363
0.657
0.721
0.721
0.598
< 0.001*
0.677
0.863
0.542
0.498
Rigidity On
Off
nil-LEDD  
Others
nil-LEDD  
Others
3.9 ±
4.4
4.2 ±
3.4
†
8.0 ±
4.2
†
7.9 ±
3.9
†
3.2 ±
2.6
2.6 ±
3.6
3.8 ±
2.9
4.4 ±
4.1
3.0 ±
3.5
2.3 ±
2.5
3.7 ±
3.6
3.4 ±
3.2
6.1 ±
3.9
5.9 ±
4.5
7.5 ±
3.7
7.0 ±
4.5
7.3 ±
4.2
6.1 ±
3.9
7.9 ±
4.4
7.2 ±
4.1
0.058
< 0.001*
0.647
0.963
0.633
0.816
< 0.001*
0.592
0.693
0.644
0.510
0.890
Bradykinesia On
Off
nil-LEDD  
Others
nil-LEDD
Others
8.7 ±
6.9
7.4 ±
4.8
15.3 ±
9.0
†
12.6 ±
5.7
†
7.2 ±
5.7
6.4 ±
5.2
9.0 ±
6.5
9.0 ±
5.8
6.8 ±
5.0
6.7 ±
4.3
8.2 ±
5.2
9.1 ±
4.7
12.7 ±
6.0
11.6 ±
7.1
13.9 ±
6.3
13.6 ±
7.2
13.0 ±
7.8
11.0 ±
5.4
14.3  ±
5.2
13.5 ±
5.4
0.235
< 0.001*
0.582
0.732
0.781
0.124
< 0.001*
0.966
0.388
0.505
0.911
0.408
Gait On
Off
nil-LEDD  
Others
nil-LEDD
Others
0.7 ±
0.8
0.8 ±
0.7
1.9 ±
1.3
†
1.9 ±
0.8
†
0.7 ±
0.6
1.0 ±
0.7
1.0 ±
0.7
1.4 ±
0.8
1.1 ±
0.7
1.0 ±
0.8
1.2 ±
0.8
1.4 ±
0.9
1.7 ±
1.2
1.6 ±
1.0
2.0 ±
1.2
1.9 ±
1.0
2.0 ±
1.2
1.5 ±
0.8
2.2 ±
1.1
1.8 ±
0.9
0.059
< 0.001*
0.668
0.406
0.264
0.255
< 0.001*
0.806
0.418
0.434
0.208
0.503
Postural 
   stability
On
Off
nil-LEDD
Others
nil-LEDD  
Others
0.8 ±
0.9
1.2 ±
0.8
†
1.6 ±
1.4
1.9 ±
0.7
0.7 ±
0.8
0.7 ±
0.8
1.2 ±
0.9
1.2 ±
0.9
0.9 ±
0.9
0.8 ±
0.8
0.9 ±
0.9
1.1 ±
0.9
1.2 ±
0.8
1.2 ±
1.0
1.7 ±
1.1
1.5 ±
1.0
1.5 ±
1.1
1.1 ±
0.9
1.6 ±
1.2
1.4 ±
0.9
0.158
< 0.001*
0.627
0.538
0.195
0.546
0.283
0.162
0.913
0.816
0.053
0.121
All data was expressed as a mean ± standard deviation. 
†13 patients are in nil-LEDD and 44 patients are in the other group. *P < 0.05. The bold-faced p-values were statisti-
cally significant (P < 0.004) after Bonferroni multiple comparison correction of 12 UPDRS III subscores. 
1, P value for within-factor of three repeated measured outcomes at the 
baseline and 6 months and 24 months after bilateral STN stimulation; 
2, P value for between-group-factor of three groups: I (both electrodes in the STN), II (only 1 electrode in 
the STN) and III (neither electrode in the STN); 
3, P value for interaction between the within-factor and between-group-factor. Abbreviations as Table 1.Paek SH, et al.  •  Electrode Position and Outcome after STN DBS
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A
B
Fig. 3. Electrode positions of 13 patients without medication after surgery. (A) The location of the electrodes are plotted based on the fused images of the 13 patients showing 
significant clinical improvement in UPDRS part III including speech with nil LEDD (in red color) and of the remaining 44 patients (in black color) at the last follow-up period of more 
than one year after surgery. Most electrodes of these 13 patients are positioned in the middle one third of the subthalamic nucleus in the axial view at the level of 3.5 mm below 
the AC-PC line (upper left), and also positioned in the subthalamic nucleus in the coronal view at the level of 3.0 mm posterior to midcommissural point (upper right) and in the 
sagittal view at the level of 12 mm lateral to the midline (lower). (B) The x, y, z coordinates of the active contacts referenced to the AC-PC midpoints in the 13 patients with nil LEDD. 
B A
D C
Fig. 4. Fused images of two brain CT scans taken after surgery. The fused images obtained from the CT scans taken at the immediate postoperative day and six months after 
surgery are aligned along the AC-PC line at the level of AC and PC in axial, sagittal, and coronal plane. The red represents the electrode extracted from the images of brain CT 
taken immediately after surgery and the gray represents the electrode extracted from the images of the brain CT taken at six months after surgery. The red and the gray elec-
trodes do not fit into each other with significant discrepancy of their position in the axial and coronal planes (A). With the adjustment of window level and width of the fused im-
ages, only the shadow of both electrodes is extracted in 3-D reconstructive rendering image of right superior oblique view (B), right posterior oblique view (C), and AP and later-
al view (D). The yellow represents the electrode extracted from the images of brain CT taken immediately after surgery and the sky-blue represents the electrode extracted from 
the images of the brain CT taken at six months after surgery. Significant discrepancy of the electrode position between the two CT scans is remarkable.
Red: brain CT 
(immediated postop.)
Gray: brain CT 
(6 months after surgery)
immediated postop. brain CT postop. 6 month brain CT immediated postop. brain CT postop. 6 month brain CT
immediated postop. brain CT postop. 6 month brain CTPaek SH, et al.  •  Electrode Position and Outcome after STN DBS
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croelectrode tracks to optimize STN targeting. 
  Kim et al. (27) found that there was a significant discrepancy 
in the implanted electrode positions between the immediate 
postoperative period and six months after DBS surgery in 53 pa-
tients with Parkinson’s disease. The considerable discrepancy 
of electrode position between the immediate postoperative CT 
scan and the brain CT taken at 6 months after surgery makes it 
difficult to precisely localize the center of the electrode with the 
fused images of preoperative MRI and the immediate postop-
erative CT scans (Fig. 4).
  Martinez-Santiesteban et al. (11) found that image artifacts in 
2.0 Tesla MRI produced by microelectrodes were highly depen-
dent not only on the magnetic susceptibility of the materials used 
but also on the size, shape and orientation of the electrodes with 
respect to main magnetic field. Lee et al. (28) compared the X-, 
Y-, Z- coordinates of the center of the electrodes estimated by 
MRI and CT in 61 patients who had taken both MRI and CT at 
least six months after bilateral STN DBS to validate the accuracy 
of MRI in electrode localization in comparison with CT scan. 
They found that the electrode location evaluated by postopera-
tive MRI had significant discrepancy with the location estimat-
ed by brain CT scan. The artifacts caused by the electrode inter-
ference of local magnetic field makes it difficult to precisely lo-
calize the center of the electrodes in MRI (Fig. 5). 
  As in the previous studies (12), we observed that the improve-
ment of symptoms, the LEDD, the neuropsychological changes 
other than speech and stimulation side effects did not vary sig-
nificantly between the patients of group I and group II in this 
series. Although the number of the patients was too small to get 
a statistical significance, there was a good deal of symptomatic 
improvements after surgery even in the patients of group III. This 
suggested that there is a significant target volume in the region 
of the STN that provides equivalent clinical efficacy, which is 
comparable with the report that McClelland et al. (26) had de-
scribed. They suggested that a DBS electrode placed anywhere 
within 6-mm-diameter cylinder centered at the presumed mid-
dle of the STN might result in similar clinical efficacy. 
  In this study the best symptom relief including speech with a 
reduced LEDD was observed in the patients whose electrodes 
were accurately positioned in both STN. There are debates re-
garding the surgical outcome of speech after bilateral STN stim-
ulation (1, 29, 30). In this study, patients of group II or III had 
B A
C D
Fig. 5. Fused images of brain CT and MRI taken after surgery. Fused images of the brain CT and the brain MRI both taken at 6 months after bilateral subthalamic stimulation 
are illustrated. The fused images obtained from the brain MRI and the brain CT taken at 6 months after bilateral subthalamic stimulation are aligned along the AC-PC line at the 
level of AC and PC in axial, sagittal, and coronal plane. The red represents the electrode extracted from the images of brain CT taken at six months after surgery and the gray 
represents the electrode extracted from the images of the brain MRI taken at six months after surgery. The center of red and gray one representing the center of electrodes ex-
tracted from brain CT and brain MRI do not fit into each other with significant discrepancy of their position in the axial, coronal, and sagittal plane of the fused images (A). With 
the adjustment of window level and width of the fused images, only the electrodes in red color are superimposed in 3-D reconstructive rendering brain MR images of superior 
anterior view (B), left anterior superior oblique view (C), and anterior posterior view (D). The discrepancy of the electrode position extracted from brain CT and the center of elec-
trode artifact from brain MRI taken at 6 months after surgery is remarkable in all three axial, sagittal, and coronal planes. 
electrode reconstructed from the brain CT 
taken at 6 months after surgery
electrode reconstructed from the brain CT 
taken at 6 months after surgery
electrode reconstructed from the brain CT 
taken at 6 months after surgeryPaek SH, et al.  •  Electrode Position and Outcome after STN DBS
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speech deterioration after bilateral STN stimulation more com-
monly than those of group I. Such speech deterioration was re-
versible when turning off the stimulation. The patients whose 
electrodes were positioned medial to the STN experienced speech 
deterioration more frequently. 
  The average LEDD at 6 and 12 months after STN stimulation 
was lower in the group I than in the group II or III in this study. 
The LEDD was zero at their last follow up in a subgroup of 13 
(36%) patients in 36 patients of group I. This subgroup of 13 pa-
tients had significant clinical improvement in sub-scores of UP-
DRS part III including speech at the last follow-up more than 
one year after surgery. These 13 patients had their stimulation 
electrodes mostly positioned within the middle one third of both 
STN on the axial view at 3.5 mm from the AC-PC line (Fig. 3).
  This study has several limitations. First, we categorized the 
electrode positions into three groups based on the plotted elec-
trode position on the axial view at the level of 3.5 mm below  
the AC-PC line in the human brain atlas of Schaltenbrand and 
Wahren (19). We assumed that the patient’s brain would con-
form to the atlas with adjustment of the length of AC-PC line 
and size of the third ventricle. However, there might be a discrep-
ancy between the real location of the electrodes in the individ-
ual brain and the location of the electrodes plotted in the human 
brain atlas confirmed to the patients. Second, we did not take 
the depth and trajectory of the electrodes into consideration to 
assess the thorough information of all four contacts in relation 
of the STN. We need further studies to assess four contacts of 
DBS electrodes in relation to the STN to recognize the best ana-
tomical structures such as dorsal STN or zona incerta for the 
modulation of each specific motor symptom. Third, it needs fur-
ther long-term follow-up in the estimation of clinical outcome 
in correlation with electrode positions identified on the CT-MR 
fused images. 
  So far little has been reported in the literature regarding the 
clinical outcome up to one year according to the electrode po-
sitions estimated at a stable period after bilateral STN stimula-
tion as in this study. The patients of group I, especially whose 
electrodes were located in the middle one third of both STN at 
3.5 mm below the anterior-posterior commissural line, had bet-
ter outcome in speech with least LEDD than two other groups. 
Our findings suggest that the better symptom relief including 
speech with a reduced LEDD is expected in the patients whose 
electrodes are accurately positioned in both STN.
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We prospectively compared the clinical outcome of the advanced Parkinson’s disease (PD) after bilateral STN stimulation according 
to electrode positions that were identified in the fused images of the preoperative MRI and the postoperative CT. We found that 
electrode position in the middle one third of both STN leads to the best outcome. It is suggested that documenting the electrode 
position at a stable period after bilateral STN stimulation is necessary for the prediction of symptomatic improvement, 
reprogramming, and possible repositioning of electrodes.